𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson’s disease

✍ Scribed by William G. Ondo; Christine Hunter; Stuart H. Isaacson; Dee E. Silver; R. Malcolm Stewart; James W. Tetrud; Anthony Davidson

Book ID
116820860
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
101 KB
Volume
17
Category
Article
ISSN
1353-8020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A pilot evaluation of the tolerability,
A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients
✍ Robert A. Hauser; Eric Molho; Heidi Shale; Simon Pedder; Ernest E. Dorflinger 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 489 KB

## Abstract Tolcapone is a potent, reversible catechol‐O‐methyltransferase (COMT) inhibitor with both peripheral and central activity. It has been demonstrated to improve motor function and allow levodopa dose reductions in Parkinson's disease (PD) patients who are experiencing either a stable resp

Zydis selegiline reduces off time in Par
Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study
✍ Cheryl H. Waters; Kapil D. Sethi; Robert A. Hauser; Eric Molho; John M. Bertoni 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB 👁 1 views

Zydis selegiline dissolves on contact with saliva and undergoes pregastric absorption. This minimizes first-pass metabolism and provides high plasma concentrations of selegiline. In this study, the efficacy and safety of Zydis selegiline was assessed in Parkinson's disease (PD) patients who were exp